三生国健:公司及关联方三生制药、沈阳三生制药有限责任公司,共同授予辉瑞PD-1/VEGF双特异性抗体SSGJ-707在全球(不含中国内地)的独家开发、生产及商业化权利。辉瑞还保留支付额外款项获取中国大陆商业化许可产品的权利。此次合作协议中,辉瑞将支付12.5亿美元不可退还且不可抵扣的首付款,最高可达48亿美元的开发、监管批准和销售里程碑付款,以及按授权地区产品销售额计算的两位数百分比梯度销售分成。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.